Bicara Therapeutics

Bicara-Therapeutics

Bicara Therapeutics is developing dual-action biologics to reprogram the tumor microenvironment and improve immunotherapy outcomes. Its lead program, ficerafusp alfa, is a first-in-class bispecific EGFR–TGFβ trap that has shown durable responses in HPV-negative head and neck cancer.

Status: IPO
Location: Cambridge, USA
Website:
bicara.com

Related news

2024-09-16
Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
2024-08-15
Bicara Therapeutics Expands Board of Directors with Appointments of Mike Powell, Ph.D., and Christopher Bowden, M.D.
2024-05-15
Bicara Therapeutics Reports Updated Interim Phase 1/1b Data of Ficerafusp Alfa (BCA101) in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
2024-03-26
Bicara Therapeutics Expands Clinical Team with Appointments of Jeltje Schulten, M.D., MBA, as SVP of Clinical and Medical Affairs and Rita Dalal, MBBS, MPH, as VP of Clinical Development
2023-12-12
Bicara Therapeutics Announces Oversubscribed $165 Million Series C Financing
2023-10-23
Bicara Therapeutics Presents Updated Interim Data from Ongoing Phase 1/1b Study of BCA101 in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) at ESMO Congress 2023
2023-10-16
Bicara Therapeutics Expands Board of Directors with Appointments of Kate Haviland and Scott Robertson
2023-07-24
Bicara Therapeutics Expands Management Team with the Appointment of David Raben, M.D., as Chief Medical Officer
2023-06-05
Bicara Therapeutics’ First-in-class Bifunctional EGFR/TGF-β Inhibitor, BCA101, Demonstrates 65% ORR in Combination with Pembrolizumab in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
2023-03-06
Bicara Therapeutics Announces Oversubscribed $108 Million Series B Financing to Advance Clinical-Stage Pipeline of Dual-Action Biologics to Treat Cancer